NETRIS Pharma successfully completes a €16.1m Series A

NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m Series A financing and the reinforcement of its Board of Directors. The round was subscribed by historical investors converting their outstanding loans, and joined by New Investors collectively investing €7.5m.

read more